Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LW347
- Development stage
- Unknown
- Lead developer
- Shanghai Longwood Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LW347 is an orally bioavailable small molecule inhibitor of programmed death-ligand 1 (PD-L1), developed by Shanghai Longwood Biopharmaceuticals for the treatment of advanced malignant tumors. By targeting PD-L1, LW347 blocks its interaction with the programmed cell death protein 1 (PD-1) receptor, thereby preventing the inhibition of T-cell activation and restoring the immune system's ability to detect and destroy tumor cells. The drug received Investigational New Drug (IND) approval in China in May 2024 and is currently in Phase 1 clinical development.
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on LW347.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LW347.